EUVIMEDEUVIMED entdecken
Crossref

Incidence, mortality and risk factors of hematologic malignancies in China from 1990 to 2021: A systematic analysis for the GBD 2021

DongHui Gan iD, Jun Lin, JinFang Zeng, JinQing Fan, ZhiQun Pan

Tumori Journal · 2026

DOI: 10.1177/03008916251410092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumori Journal, 2026. Verfasst von DongHui Gan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Hospital of Putian University, Putian City, Fujian Province, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Fujian Provincial Natural Science Foundation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to systematically analyze the incidence, mortality, and risk factors of hematologic malignancies and their subtypes in China from 1990-2021.

Methods

The study utilized data from the Global Burden of Disease 2021 database. Trends in incidence and mortality rates of hematologic malignancies from 1990-2021 were measured using estimated annual percentage change (EAPC) with 95% confidence intervals. Future burden in China up to 2035 was projected using Bayesian age-period-cohort modeling.

Results

Between 1990 and 2021, China saw rising age-standardized incidence rates for multiple myeloma, non-Hodgkin lymphoma, and leukemia, but a decline for Hodgkin lymphoma. Mortality decreased for leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, while increasing for multiple myeloma. Among leukemia subtypes, incidence fell for acute myeloid, chronic myeloid, and other leukemias but rose for acute and chronic lymphoid leukemias. Mortality declined across all five subtypes. Males had higher incidence and mortality than females for all hematologic malignancies. The 65–69 age group had the highest number of cases and deaths. Children under 5 years of age were most affected by leukemia, mainly acute lymphoid leukemia. High BMI was a significant risk factor. Projections to 2035 suggest continued increases in incidence and mortality for multiple myeloma, but declining leukemia mortality. Incidence of acute lymphoblastic and other leukemias is expected to fall, with mortality improving for all leukemia subtypes.

Conclusions

China’s hematologic malignancy burden remained high in 2021 and is projected to persist through 2035. BMI is a key driver, highlighting the need for targeted control measures to reduce this burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsHumansChinaRisk FactorsMaleFemaleIncidenceMiddle AgedAgedAdultChild, PreschoolChildAdolescentMultiple MyelomaInfantYoung AdultBayes TheoremAged, 80 and over

Stichwörter der Autor:innen

Chinaburden of diseasehematologic malignancyincidencemortalityrisk factor

Autor:innen und Institutionen

  • Department of Hematology, Affiliated Hospital of Putian University, Putian City, Fujian Province, China.
  • Department of Clinical Laboratory, Affiliated Hospital of Putian University, Putian City, Fujian Province, China.

ORCID-Profile: DongHui Gan

Förderung

  • Fujian Provincial Natural Science Foundation Project

Zitieren

APA

Gan, D., Lin, J., Zeng, J., Fan, J., & Pan, Z. (2026). Incidence, mortality and risk factors of hematologic malignancies in China from 1990 to 2021: A systematic analysis for the GBD 2021. Tumori Journal. https://doi.org/10.1177/03008916251410092

Vancouver

Gan D, Lin J, Zeng J, Fan J, Pan Z. Incidence, mortality and risk factors of hematologic malignancies in China from 1990 to 2021: A systematic analysis for the GBD 2021. Tumori Journal. 2026. doi:10.1177/03008916251410092

BibTeX
@article{Gan2026,
  author = {Gan, DongHui and Lin, Jun and Zeng, JinFang and Fan, JinQing and Pan, ZhiQun},
  title = {Incidence, mortality and risk factors of hematologic malignancies in China from 1990 to 2021: A systematic analysis for the GBD 2021},
  journal = {Tumori Journal},
  year = {2026},
  doi = {10.1177/03008916251410092}
}
Kostenlos starten →